European Medicines Agency Committee Provides A Positive Opinion On Calliditas' Application For Orphan Drug Designation For Setanaxib In Alport Syndrome
Portfolio Pulse from Benzinga Newsdesk
The European Medicines Agency Committee has provided a positive opinion on Calliditas' application for orphan drug designation for Setanaxib in Alport Syndrome. This could potentially lead to a new treatment option for patients with this rare genetic disorder.
October 05, 2023 | 8:49 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Calliditas Therapeutics' application for orphan drug designation for Setanaxib in Alport Syndrome received a positive opinion from the European Medicines Agency Committee. This could potentially boost the company's stock in the short term.
The positive opinion from the European Medicines Agency Committee is a significant step towards the approval of Setanaxib as an orphan drug. This could potentially open up a new revenue stream for Calliditas, which would likely have a positive impact on the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100